Guilin Sanjin Pharmaceutical Co., Ltd. (002275.SZ)
CNY 13.63
(0.15%)
CNY 13.63
(0.15%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 528.33 Million CNY | 13.41% |
| 2022 | 465.87 Million CNY | -23.51% |
| 2021 | 609.09 Million CNY | 52.45% |
| 2020 | 399.54 Million CNY | 116.87% |
| 2019 | 184.22 Million CNY | 84.23% |
| 2018 | 100 Million CNY | 0.0% |
| 2017 | 100 Million CNY | 100.0% |
| 2016 | 50 Million CNY | 0.0% |
| 2015 | 50 Million CNY | 0.0% |
| 2014 | 50 Million CNY | 136.97% |
| 2013 | 21.1 Million CNY | 1818.18% |
| 2012 | 1.1 Million CNY | 0.0% |
| 2011 | 1.1 Million CNY | 0.0% |
| 2010 | 1.1 Million CNY | -95.79% |
| 2009 | 26.1 Million CNY | -85.35% |
| 2008 | 178.1 Million CNY | -0.5% |
| 2007 | 179 Million CNY | 1932.65% |
| 2006 | 8.8 Million CNY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 486.72 Million CNY | 15.11% |
| 2024 Q3 | 433.44 Million CNY | -1.72% |
| 2024 Q1 | 422.82 Million CNY | -19.97% |
| 2023 Q3 | 491.39 Million CNY | -3.3% |
| 2023 Q4 | 528.33 Million CNY | 7.52% |
| 2023 Q1 | 614.19 Million CNY | 31.84% |
| 2023 Q2 | 508.18 Million CNY | -17.26% |
| 2023 FY | 528.33 Million CNY | 13.41% |
| 2022 FY | 465.87 Million CNY | -23.51% |
| 2022 Q3 | 562.98 Million CNY | -9.99% |
| 2022 Q2 | 625.49 Million CNY | 3.12% |
| 2022 Q4 | 465.87 Million CNY | -17.25% |
| 2022 Q1 | 606.59 Million CNY | -0.41% |
| 2021 Q2 | 525.92 Million CNY | -0.59% |
| 2021 Q4 | 609.09 Million CNY | 17.74% |
| 2021 FY | 609.09 Million CNY | 52.45% |
| 2021 Q1 | 529.06 Million CNY | 32.42% |
| 2021 Q3 | 517.34 Million CNY | -1.63% |
| 2020 Q1 | 265.36 Million CNY | 44.04% |
| 2020 Q3 | 340 Million CNY | 19.62% |
| 2020 Q4 | 399.54 Million CNY | 17.51% |
| 2020 Q2 | 284.23 Million CNY | 7.11% |
| 2020 FY | 399.54 Million CNY | 116.87% |
| 2019 Q1 | 100 Million CNY | 0.0% |
| 2019 FY | 184.22 Million CNY | 84.23% |
| 2019 Q4 | 184.22 Million CNY | 45.13% |
| 2019 Q3 | 126.94 Million CNY | -2.35% |
| 2019 Q2 | 130 Million CNY | 30.0% |
| 2018 Q2 | 30 Million CNY | -70.0% |
| 2018 Q4 | 100 Million CNY | 0.0% |
| 2018 Q3 | 100 Million CNY | 233.33% |
| 2018 Q1 | 100 Million CNY | 0.0% |
| 2018 FY | 100 Million CNY | 0.0% |
| 2017 Q1 | 70 Million CNY | 40.0% |
| 2017 Q2 | 100 Million CNY | 42.86% |
| 2017 Q3 | 100 Million CNY | 0.0% |
| 2017 Q4 | 100 Million CNY | 0.0% |
| 2017 FY | 100 Million CNY | 100.0% |
| 2016 Q2 | 50 Million CNY | 0.0% |
| 2016 Q4 | 50 Million CNY | 0.0% |
| 2016 Q1 | 50 Million CNY | 0.0% |
| 2016 FY | 50 Million CNY | 0.0% |
| 2016 Q3 | 50 Million CNY | 0.0% |
| 2015 Q4 | 50 Million CNY | 0.0% |
| 2015 Q3 | 50 Million CNY | 0.0% |
| 2015 Q2 | 50 Million CNY | 0.0% |
| 2015 Q1 | 50 Million CNY | 0.0% |
| 2015 FY | 50 Million CNY | 0.0% |
| 2014 Q1 | 20 Million CNY | -5.21% |
| 2014 FY | 50 Million CNY | 136.97% |
| 2014 Q4 | 50 Million CNY | 0.0% |
| 2014 Q3 | 50 Million CNY | 150.0% |
| 2014 Q2 | 20 Million CNY | 0.0% |
| 2013 Q2 | 1.1 Million CNY | 0.0% |
| 2013 Q1 | 1.1 Million CNY | 0.0% |
| 2013 Q3 | 21.1 Million CNY | 1818.18% |
| 2013 Q4 | 21.1 Million CNY | 0.0% |
| 2013 FY | 21.1 Million CNY | 1818.18% |
| 2012 Q3 | 71.1 Million CNY | 0.0% |
| 2012 FY | 1.1 Million CNY | 0.0% |
| 2012 Q1 | 1.1 Million CNY | 0.0% |
| 2012 Q2 | 71.1 Million CNY | 6363.64% |
| 2012 Q4 | 1.1 Million CNY | -98.45% |
| 2011 FY | 1.1 Million CNY | 0.0% |
| 2011 Q4 | 1.1 Million CNY | 0.0% |
| 2011 Q2 | 1.1 Million CNY | 0.0% |
| 2011 Q1 | 1.1 Million CNY | 0.0% |
| 2011 Q3 | 1.1 Million CNY | 0.0% |
| 2010 FY | 1.1 Million CNY | -95.79% |
| 2010 Q1 | 26.1 Million CNY | 0.0% |
| 2010 Q4 | 1.1 Million CNY | -95.79% |
| 2010 Q3 | 26.1 Million CNY | 0.0% |
| 2010 Q2 | 26.1 Million CNY | 0.0% |
| 2009 FY | 26.1 Million CNY | -85.35% |
| 2009 Q3 | 26.1 Million CNY | -85.18% |
| 2009 Q4 | 26.1 Million CNY | 0.0% |
| 2009 Q2 | 176.1 Million CNY | 0.0% |
| 2008 Q4 | 178.1 Million CNY | 0.0% |
| 2008 FY | 178.1 Million CNY | -0.5% |
| 2007 FY | 179 Million CNY | 1932.65% |
| 2006 FY | 8.8 Million CNY | 0.0% |